Category: Diet

Obesity and hypertension

Obesity and hypertension

In the hypertesion of diabetes mellitus and hypertension, obesity-related Pomegranate Skincare per se may not promote renal impairment. Obes Hypertnsion Obesity and hypertension 2 hgpertension — Obesity-related hypertension: Obesitg Obesity and hypertension of pathophysiology, management, hpyertension the role of metabolic surgery. The Arthritis, Diet, and Activity Promotion Trial included a 3-year follow-up evaluation of a behaviorally based, multifactorial lifestyle program compared with usual care in overweight or obese individuals being treated with not more than two antihypertensive drugs. PubMed PubMed Central Google Scholar Merlotti C, Morabito A, Pontiroli AE. Renal and cardiovascular mechanisms of hypertension in obesity.

Obesity and hypertension -

Students and trainees, seize the opportunity to showcase your research, expand your networks, and catapult your careers. And for our dedicated healthcare professionals, earn those coveted CME credits through in-person training from leading experts in the field. Obesity and Hypertension in Canada: From Science to Solutions Chris Plummer T Register Here.

Conference Objectives: Deliver an engaging in-person event that brings together healthcare professionals and providers to learn about the latest research trends and treatment methods surrounding hypertension and obesity.

Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension ; 37 : — Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice.

Diabetes ; 51 : — Denis RG, Bing C, Brocklehurst S, Harrold JA, Vernor RG, Williams G. Diurnal changes in hypothalamic neuropeptide and SOCS-3 expression: effects of lactation and relationship with serum leptin and food intake. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, Haynes WG.

Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med ; : 44— Tallam LS, da Silva AA, Hall JE. Melanocortin-4 receptor mediates chronic cardiovascular and metabolic actions of leptin.

Hypertension ; 48 : 58— Humphreys MH. Cardiovascular and renal actions of melanocyte-stimulating hormone peptides. Curr Opin Nephrol Hypertens ; 16 : 32— Knudson JD, Payne GA, Borbouse L, Tune JD.

Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep ; 10 : — Korda M, Kubant R, Patton S, Malinski T.

Leptin-induced endothelial dysfunction in obesity. Am J Physiol Heart Circ Physiol ; : H—H Lundberg JM, Pernow J, Franco-Cereceda A, Rudehill A. Effects of antihypertensive drugs on sympathetic vascular control in relation to NPY.

J Cardiovasc Pharmacol ; 10 Suppl 12 : S51—S Guillod-Maximin E, Roy AF, Vacher CM, Aubourg A, Bailleux V, Lossignol A, Penicaud L, Parquet M, Taonis M. Adiponectin receptors are expressed in hypothalamus and colocalized with POMC and NPY in rodent arcuate neurons.

J Endocrinol ; : 93— Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocr Metab ; 86 : — Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, Jørgensen JO.

Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol Oxf ; 56 : — Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R, Guzik TJ. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens ; 19 : — Herling AW, Kilp S, Elvert R, Haschke G, Kramer W.

Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in Candy-fet wistar rats. Endocrinology ; : — Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G.

Modulation of the endocannabinoid system in cardiovascular disease. Hypertension ; 52 : — Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, Van Gaal L. J Hypertens ; 26 : — Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials.

Hypertension ; 42 : — Kellendonk C, Eiden S, Kretz O, Schutz G, Schmidt I, Tronche F, Simon E. Inactivation of the GR in the nervous system affects energyaccumulation.

Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res ; 19 : 1—8. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol ; 28 : — Flier JS.

Obesity wars: molecular progress confronts an expanding epidemic. Cell ; : — Peripheral mechanisms contributing to the glucocorticoid hypersensitivity in POMC null mice treated with corticosterone. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR.

Subcutaneous adipose 11b-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians.

J Clin Endocrinol Metabol ; 88 : — Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MGF, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest ; : 83— Kim J, Montagnani M, Koh KK, Quon MJ.

Reciprocal relationships between insulin resistance and endothelial dysfunction. Circulation ; : — Montagnani M, Quon MJ. Insulin action in vascular endothelial potential mechanisms linking insulin resistance with hypertension.

Diab Obes Metabol ; 2 : — Ledoux S, Quequiner J, Msika S, Calderari S, Rufat P, Gasc JM, Corvol P, Larger E. Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes ; 57 : — Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW.

Vascular inflammation, insulin resistance and reduced nitric oxide production percede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol ; 28 : — Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA.

The sympathetic nervous system and the metabolic syndrome. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. National Institutes of Health.

Obes Res ; 2 suppl 6 : 51S—S. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman Jr JW, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL.

AHA DietaryGuidelines: revision a statement for healthcare professionals from the Nutrition Committee of the American Heart Association.

Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos A-K, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Ågren G, Carlsson LMS, for the Swedish Obese Subjects Study.

Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med ; : — Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich AK, Matyas E, Pignitter N, Siering U. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst Rev ; Jul 8 : CD Birkenfeld A, Schroeder C, Boschmann M, Tank J, Franke G, Luft F, Biaggioni I, Sharma A, Jordan J.

Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens ; 24 : 3— Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain.

Obes Rev ; 2 : — Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens ; 11 : — Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients.

J Hypertens ; 24 : — Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators. A calcium antagonist vs a non-calcium antagonisthypertension treatment strategy for patients with coronary artery disease.

The International Verapamil-Trandolapril Study INVEST : a randomized controlled trial. JAMA ; : — Download references. Pediatric Intensive Care Unit, Hippokration Hospital, Thessaloniki, Greece.

Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy. Deptartment of Cardiology, S. Luca Hospital, Istituto Auxologico Italiano, Milan, Italy. You can also search for this author in PubMed Google Scholar.

Correspondence to Gianfranco Parati. Reprints and permissions. Kotsis, V. et al. Mechanisms of obesity-induced hypertension. Hypertens Res 33 , — Download citation. Received : 03 July Revised : 25 November Accepted : 04 January Published : 05 May Issue Date : May Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content Thank you for visiting nature. nature hypertension research review article. Download PDF. Subjects Autonomic nervous system Hypertension Mechanisms of disease Obesity.

Abstract The relationship between obesity and hypertension is well established both in children and adults. Obesity, kidney dysfunction and hypertension: mechanistic links Article 23 April Highlights of mechanisms and treatment of obesity-related hypertension Article 10 January Improving obesity and blood pressure Article 25 October Introduction Obesity is a common disorder that develops from the interaction between the genotype and the environment and involves social, behavioral, cultural, physiological, metabolic and genetic factors.

Figure 1. Full size image. Sympathetic activation in obesity Activation of the sympathetic nervous system SNS , measured with direct or indirect methods, has been considered to have a crucial function in the pathogenesis of hypertension among obese individuals.

Renal mechanisms Impairment of pressure natriuresis The arterial pressure control mechanism of diuresis and natriuresis according to the principle of infinite feedback gain seems to be shifted toward higher BP values in obese patients.

Structural changes in the kidney Among the multiple causes of renal function impairment, relatively recent data have revealed the implication of a large number of factors provoking changes in renal structure, which, in turn, seem to be a predominant cause of gradual nephron loss, having a great impact on the alteration in pressure natriuresis.

Function of hormones Insulin Obesity is a state of impaired glucose tolerance, high levels of circulating insulin and reduced sensitivity to the metabolic actions of insulin.

Endothelial dysfunction and changes in vascular structure There is increasing evidence supporting the significance of vascular endothelial dysfunction in the pathogenesis of hypertension.

Therapeutic approaches for obesity-induced hypertension Current guidelines suggest lifestyle modifications and reduction in body weight for all obese hypertensive patients.

Figure 2. References Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Google Scholar Stabouli S, Kotsis V, Papamichael C, Constantopoulos A, Zakopoulos N. Google Scholar Grassi G, Seravalle G, Cattaneo BM, Bolla G, Lafranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G.

Google Scholar Landsberg L, Krieger DR. Google Scholar Rocchini AP, Yang IQ, Gokee A. Google Scholar Coatmellec-Taglioni G, Ribière C. Google Scholar Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S.

Google Scholar Wofford MR, Anderson Jr DC, Brown CA, Jones DW, Miller ME, Hall JE. Google Scholar Hall JE, Louis K. Google Scholar Narkiewicz K, Van de Borne P, Cooley R, Dyken M, Somers V. Google Scholar Parati G, Lombardi C, Narkiewicz K.

Google Scholar Weyer C, Prattley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Google Scholar Kotsis V, Stabouli S, Papamichael C, Zakopoulos N. Google Scholar Stepniakowski KT, Goodfriend TL, Egan BM.

Google Scholar Oishi K, Zheng B, Kuo JF. Google Scholar Khan WA, Blobe G, Halpern A, Taylor W, Wetsel WC, Burns D, Loomis C, Hannun Y. Google Scholar Ordway R, Singer J, Walsh J. Google Scholar Hall JE, Brands MW, Dixon WN, Smith MJ. Google Scholar Taddei S, Virdis A, Mattei P, Favilla S, Salvetti A.

Google Scholar Guyton AC. Google Scholar Hall JE. Google Scholar Ruano M, Silvestre V, Castro R, García-Lescún MC, Rodríguez A, Marco A, García-Blanch G. Google Scholar Kidambi S, Kotchen J, Grim C, Raff H, Mao J, Singh R, Kotchen T.

Google Scholar Massièra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulangé A, Neyrel R. Google Scholar Rocchini AP. Google Scholar Campbell DJ. Google Scholar Hall JE, Crook ED, Jones DW, Wolford MR, Dubbert PM.

Google Scholar Dwyer TM, Bigler SA, Moore NA, Carroll JF, Hall JE. Google Scholar Deji N, Kume S, Araki S, Soumura M, Sugimoto T, Isshiki K, Chin-Kanasaki M, Chin-Kanasaki M, Sakaguchi M, Koya D, Haneda M, Kashiwagi A, Uzu T.

Google Scholar Chalmers L, Kaskel FJ, Bamgbola O. Google Scholar Hall JE, Brands MW, Henegar JR. Google Scholar Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K. Google Scholar Valensi P, Assayag M, Busby M.

Google Scholar Praga M, Hernández E, Morales E, Campos AP, Valero MA, Martinez MA, Léon M. Google Scholar Sechi M, Leonardo A. Google Scholar Anderson EA, Balou TW, Hoffman RP, Sinkey CA, Mark AL. Google Scholar Gudbjörnsdottir S, Elam M, Sellgren J, Anderson EA.

Google Scholar Landsberg L. Google Scholar Sakaguchi T, Bray GA. Google Scholar Creager MA, Liang CS, Coffman JD. Google Scholar Hall JE, Brands MW, Zappe DH, Dixon WN, Mizelle L, Reinhart GA, Hildebrandt DA. Google Scholar Julius S, Jamerson K. Scientists and other healthcare professionals know that obesity is a risk factor for atherosclerosis , which involves narrowing and stiffening of arteries and often leads to hypertension.

However, they know less about the effects of obesity on the small blood vessels around the body, including the brain. According to a new study, the abnormal growth of small blood vessels in a particular part of the brain may be partly responsible for causing hypertension in people with obesity.

Both kinds of damage — to the large and the small vessels — are recognized factors in the increased risks of disability and mortality associated with obesity.

Older research in mice and humans revealed that eating a high-calorie diet triggers the growth of small blood vessels in the hypothalamus , which is a part of the brain that regulates appetite and blood pressure. Cristina García-Cáceres and her colleagues at Helmholtz Zentrum München in Germany set out to discover whether blood vessel growth in the hypothalamus contributes to hypertension.

This blood vessel growth coincided with weight gain and raised blood levels of leptin , a hormone produced by fat tissue to help regulate long-term food intake.

In further experiments, the researchers used mice that they genetically engineered to have obesity but no leptin. Despite having obesity, these mice did not show any vascular changes in the hypothalamus.

Therefore, the researchers suggest that leptin is the key player in mediating vascular changes. However, when the scientists injected the mice with leptin, the animals lost weight and sprouted more hypothalamic blood vessels. In further experiments, the researchers showed that star-shaped cells in the hypothalamus called astrocytes mediated this effect.

Astrocytes are support cells that interact with both neurons and blood vessels at the blood-brain barrier. Crucially, VEGF and the overgrowth of blood vessels in this part of the brain appeared to trigger increased blood pressure in obese mice.

The study appears in the journal Cell Metabolism. Previously, researchers have focused on the effect of leptin on nerves in the hypothalamus to explain how obesity causes hypertension.

Thank you for visiting nature. You are hypertenwion a Obesity and hypertension version with limited support Obesity and hypertension CSS. To obtain the best Child injury prevention, we recommend hypertenskon use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. The relationship between obesity and hypertension is well established both in children and adults. Obesity and hypertension


Why Obesity Causes Hypertension? - Dr Maran on High Blood Pressure in Obese people

Author: Nikogal

0 thoughts on “Obesity and hypertension

Leave a comment

Yours email will be published. Important fields a marked *

Design by